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In Brief
Mitochondrial function is an important
determinant of skeletal muscle
homeostasis. Das et al. report that
activation of ATP citrate lyase (ACL) by
IGF1 in skeletal muscle increases
cardiolipin content and mitochondrial
complex activity and improves
mitochondrial function, revealing how the
IGF1/ACL pathway combines anabolic
signaling with energy production.
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Mitochondrial dysfunction is associatedwith skeletal
muscle pathology, including cachexia, sarcopenia,
and the muscular dystrophies. ATP citrate lyase
(ACL) is a cytosolic enzyme that catalyzes mitochon-
dria-derived citrate into oxaloacetate and acetyl-
CoA. Here we report that activation of ACL in skeletal
muscle results in improved mitochondrial function.
IGF1 induces activation of ACL in an AKT-dependent
fashion. This results in an increase in cardiolipin,
thus increasing critical mitochondrial complexes
and supercomplex activity, and a resultant increase
in oxygen consumption and cellular ATP levels.
Conversely, knockdown of ACL in myotubes not
only reduces mitochondrial complex I, IV, and V
activity but also blocks IGF1-induced increases in
oxygen consumption. In vivo, ACL activity is associ-
ated with increased ATP. Activation of this IGF1/
ACL/cardiolipin pathway combines anabolic sig-
naling with induction of mechanisms needed to pro-
vide required ATP.
INTRODUCTION
Dysregulation in mitochondrial oxidative phosphorylation
(OXPHOS) as well as mitochondrial complex activity is
associated with various skeletal muscle pathologies, including
cachexia, sarcopenia, and the muscular dystrophies (Julienne
et al., 2012; Marzetti et al., 2013; Szendroedi et al., 2008;
Wang et al., 2010; White et al., 2011). Mitochondrial complexes
are organized into several supercomplexes that facilitate the flow
of electrons and thusmake the systemmore efficient, minimizing
ROS generation (Lapuente-Brun et al., 2013). It was also specu-
lated that complex stability is influenced by the organization of
supercomplexes. Recently, Ikeda et al. showed that mitochon-
drial activity is impaired and ATP content decreased by lack of
supercomplex formation (Ikeda et al., 2013).
Anabolic stimuli like exercise have a positive impact on skel-
etal muscle strength, endurance, and aerobic capacity by
increasing protein synthesis, in addition to mitochondrial and
contractile function of skeletal muscle (Egan and Zierath, 2013;
Egerman andGlass, 2014; Riedl et al., 2010). The positive effects868 Cell Metabolism 21, 868–876, June 2, 2015 ª2015 Elsevier Inc.of exercise extend to diseased populations and to the elderly
(Fiatarone et al., 1990; Hansen et al., 2010; Jeppesen et al.,
2006). Some of these effects are elicited in response to contrac-
tile activity and mediated by anabolic factors such as insulin
growth factor 1 (IGF1) (Schiaffino et al., 2013).
IGF1 is an anabolic growth factor that induces hypertrophy
and blocks atrophy in skeletal muscle by activating the PI3K/
AKT/mTOR pathway (Egerman and Glass, 2014). In addition to
its anabolic and anti-catabolic effects, IGF1 stimulates fatty
acid (FA) uptake and glucose metabolism (Clemmons, 2012).
Whereas both FAs and glucose can be used to generate ATP,
glucose can also support de novo lipid synthesis via cytosolic
citrate metabolism (Vander Heiden et al., 2009), which is an
important step tomeet the demand ofmembrane expansion dur-
ing skeletal muscle growth. Cardiolipin is a phospholipid specific
to the inner mitochondrial membrane, where it plays an impor-
tant role in structural organization and function of these mem-
branes (Paradies et al., 2014; Ren et al., 2014).
ATP citrate lyase (ACL) is a cytosolic enzyme that catalyzes the
conversion of mitochondria-derived citrate into oxaloacetate
and acetyl-CoA, which are further utilized as building blocks
for lipid synthesis and acetylation. Acetyl-CoA is vital for acety-
lation reactions that modify proteins including histones, affecting
their functions (Lee et al., 2014;Wellen et al., 2009). In the current
study, we investigated the role of ACL in regulating lipid meta-
bolism and mitochondrial function in skeletal muscle and
whether metabolic effects orchestrated by IGF1 are regulated
by ACL.RESULTS
IGF1 Induces De Novo Lipid Synthesis through
PI3K/AKT/ACL
Conversion of glucose to lipids requires several steps, terminat-
ing with mitochondrial export of citrate into the cytosol. ACL then
catalyzes conversion of cytosolic citrate to oxaloacetate and
acetyl-CoA (Chypre et al., 2012). Phosphorylation of ACL at
S455 was shown to be regulated by PI3K/AKT, and this phos-
phorylation has been reported to stimulate ACL enzymatic activ-
ity (Berwick et al., 2002; Potapova et al., 2000). Since IGF1 also
activates the PI3K/AKT pathway, we asked if IGF1 could in-
crease ACL phosphorylation. IGF1 stimulated ACL phosphoryla-
tion at S455 in a PI3K-dependent manner, since the PI3K inhibitor
LY294002 significantly reduced it (Figure 1A). IGF1 also induced
ACL phosphorylation on two different sites, T447/S451, and this
effect was also inhibited by LY294002 (Figure S1A). However,
rapamycin treatment did not affect pACL S455 or T447/S451, sug-
gesting that mTORC1 signaling was not required downstream of
IGF1 treatment (Figure S1B).
Overexpressing dominant-negative AKT (dnAKT) reduced
ACL phosphorylation following IGF1 treatment (Figure 1B), indi-
cating that AKT regulates ACL phosphorylation. To determine if
AKT was sufficient to induce ACL phosphorylation, we overex-
pressed a constitutively active mutant, myristoylated AKT
(myr-AKT), in primary human skeletal myotubes. Increased
ACL phosphorylation induced by myr-AKT demonstrated that
AKT activity is not only necessary (Figure 1C) but sufficient for
phosphorylation of ACL at S455 and at T447/S451 (Figures 1C
and S1C).
To add physiological context to the in vitro data, the phosphor-
ylation status of ACL was analyzed in muscles of aged mice. As
shown in Figure 1D, the phosphorylation of ACL at T447/S451 was
significantly downregulated in the tibialis (TA) muscle of 24-
month-old mice compared to younger animals. Furthermore,
signaling upstream of ACL was also downregulated in old
mice. Transcript levels of IGF1 were significantly decreased (Fig-
ure S1D), as were total protein levels of AKT and AKT phosphor-
ylation on S473 in the tibialis muscle of aged mice (Figure 1D).
IGF1 regulates glucose uptake via the PI3K/AKT pathway
(Clemmons, 2012). To test if the glucose to lipid conversion in
response to IGF1 was regulated by ACL, myotubes were incu-
bated with C14-pyruvate, and the rate of lipid synthesis was
analyzed. Similar to what has been demonstrated in other cell
types (Hatzivassiliou et al., 2005), lipid synthesis was signifi-
cantly downregulated (33%) after ACL knockdown (Figure 1E).
The rate of pyruvate incorporation into lipid was significantly
increased by IGF1 treatment; ACL knockdown and the PI3K in-
hibitor LY294002 reduced IGF1-mediated stimulation signifi-
cantly (Figures 1E and 1F). Delta 6 desaturase expression, an
important enzyme for the metabolism of polyunsaturated FAs
(Kro¨ger and Schulze, 2012), was increased by both ACL overex-
pression and IGF1 treatment (Figure S1E). Collectively, the data
show that the IGF1/PI3K/AKT pathway stimulates ACL phos-
phorylation and de novo lipid synthesis via ACL in skeletal mus-
cle. Also, ACL phosphorylation is reduced in tibialis muscle of old
versus young mice; this effect could be a consequence of
decreased IGF1 signaling in aged mice.
ACL Regulates Cardiolipin Synthesis and Content in
Skeletal Muscle
Since ACL activity is necessary for lipid synthesis, we asked
whether ACL activity might also influence the synthesis and/or
content of cardiolipin in skeletal muscle, thus regulating
OXPHOS activity as well as mitochondrial complex activities.
To examine the effect of ACL in vivo, adeno-associated vi-
ruses (AAVs) expressing wild-type ACL (AAV-ACL) or GFP
(AAV-GFP) were injected into the TA muscles, and the expres-
sion of ACLwas confirmed at themRNA level (Figure S2A). In vivo
expression of ACL for 4 weeks caused a significant increase of
cardiolipin (37%) in the mitochondria (Figure 2A). The increase
in cardiolipin induced by ACL was not accompanied by an in-
crease in the expression of genes involved in cardiolipin synthe-
sis such as Crls1, Taz, and Ptpmt1 (Figure 2B). However, when
we used short hairpin RNA (AAV-shACL) to downregulate ACLCexpression in vivo (Figure S2A), we observed a significant
decrease of Crls1 and Taz but not of Ptpmt1 mRNA levels (Fig-
ure 2B). Given its positive effect on lipid synthesis, we tested
whether IGF1 was able to perturb cardiolipin levels in mitochon-
dria isolated from human myotubes treated with IGF1 for 30 hr.
As shown in Figure 2C, IGF1 treatment increased cardiolipin
content in a PI3K-dependent manner. Not surprisingly, insulin
induced similar effects (Figure S2B). Together these results
demonstrate that ACL expression is required to maintain cardio-
lipin-relevant gene expression, and activation of ACL in vivo can
increase cardiolipin without perturbing gene expression. Inter-
estingly, we found that cardiolipin content and transcript levels
of Taz and Ptpmt1, enzymes that are required for cardiolipin
formation, are reduced in TA of old compared to young mice
(Figures 2D and 2E), whereas exercise resulted in a significant in-
crease in cardiolipin content and expression of Crls1, Taz, and
Ptpmt1 (Figures 2F and 2G).
ACL Regulates Mitochondrial Supercomplex and
Complex Levels and Activity
Cardiolipin aids in binding the complexes together into a super-
complex (Mejia et al., 2014; Paradies et al., 2014; Ren et al.,
2014). Since cardiolipin was significantly increased in tibialis
(TA) muscle by ACL overexpression, we analyzed the content
and activity of mitochondrial complexes as well as supercom-
plexes in the mitochondria isolated from TA muscle of mice in-
fected with AAV-ACL or AAV-GFP. Coomassie staining revealed
a significant increase in supercomplex formation containing
complex I following overexpression of ACL in TA (Figures 3A
and 3B). Interestingly, ACL overexpression also significantly
increased the abundance of complex II, III, IV, and V (Figures
3A and 3C). These data support the model that supercomplex
formation could result in stabilization of individual complexes
as well. To support the results shown in Figures 3A–3C, we
analyzed the protein levels of specific components of mitochon-
drial complexes by immunoblotting and observed significantly
increased protein content for NDUFB8 (complex I) and SDHB
(complex II) (Figure 3D). Complex I is known to assemble in
supercomplexes containing complex III as well as complex IV,
which stabilizes complex I as well as increases its activity.
Accordingly, we observed significant increase in complex I activ-
ity as well as activity of supercomplex I+III2+IV, as assessed by
in-gel activity assay performed after native PAGE of mitochon-
dria obtained from AAV-ACL-infected TA (Figure 3E). Finally,
ACL overexpression resulted in increased activity of complex
II, IV, and V, but not of complex III (Figure 3F). Thus, increased
complex content and composition accounts for the overall
enhanced mitochondrial complex activity observed in the skel-
etal muscle overexpressing ACL.
IGF1 Induces Mitochondrial Respiration through ACL
Mitochondria generate ATP through the process of respiration
and OXPHOS (Stephenson and Hawley, 2014). We found that
IGF1 induces mitochondrial respiration in myotubes, as deter-
mined using a Seahorse XF-96 flux analyzer (Figure 4A). How-
ever, knocking down ACL significantly decreased OXPHOS
activity (Figure 4A). From basal conditions, IGF1 induced oxygen
consumption by 80%, whereas ACL downregulation not only
decreased the oxygen consumption by 52% but also blockedell Metabolism 21, 868–876, June 2, 2015 ª2015 Elsevier Inc. 869
Figure 1. IGF1 Promotes De Novo Lipid Synthesis via Activation of ACL
(A) Differentiated human skeletal muscle cells (HuSkMCs) were treated with vehicle or 30 nM IGF1 as indicated ± 1 mMLY294002. pACL (S455) and total ACLwere
analyzed. Graphs show densitometry of 3–5 independent experiments, and a representative blot is shown. ANOVA followed by Dunnett’s multiple comparison
test was used.
(legend continued on next page)
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the effect of IGF1, indicating IGF1was acting via ACL (Figure 4A).
IGF1 increased maximal respiration by 85% and reserve ca-
pacity of the myotubes by 90%. Knocking down ACL not
only led to a decrease of 53%, and 53% maximal respiration
and reserve capacity, but also decreased the IGF1-induced ef-
fect by 59% and 60%, respectively (Figure 4A). In addition,
IGF1 increased the coupling efficiency of the myotubes by
104%, whereas downregulation of ACL decreased the same
by 90% and by 65% in the presence of IGF1 (Figure 4A).
In order to understand the mechanism by which ACL en-
hances mitochondrial respiration, we analyzed mitochondrial
number in myotubes after knocking down or overexpressing
ACL. There was no significant change in mitochondrial DNA after
normalizing to nuclear DNA (Figure S3A). Thus, the altered mito-
chondrial function of myotubes by ACL is not a consequence of
modified mitochondrial number. Next, we analyzed individual
mitochondrial complex activities in isolated mitochondria from
myotubes after overexpressing or downregulating ACL. Overex-
pressing ACL induced an increase of 67%, 38%, and 93%
in complex I, IV, and V, respectively, whereas knockdown of ACL
led to a decrease of 42%, 25%, and 70% in complex I, IV,
and V, respectively (Figure 4B). Complex II activities showed
similar trends; however, the differences failed to reach signifi-
cance in three independent experiments (Figure 4B). Because
mitochondria produce reactive oxygen species (ROS) as a natu-
ral byproduct of electron transport chain activity, and supercom-
plexes control ROS generation by the respiratory chain (Sullivan
and Chandel, 2014), we asked if ACL overexpression perturbs
ROS generation. As shown in Figure S3B, ACL overexpression
in myotubes did not affect ROS.
In addition to increased mitochondrial OXPHOS activity,
cellular ATP content was increased by 43% by IGF1 treatment
(Figure 4C). AlteredOXPHOS activity andmitochondrial complex
activity by ACL knockdown or overexpression resulted in 35%
decrease or75% increase in cellular ATP content, respectively
(Figure 4C), also demonstrating that IGF1-mediated increases in
ATP require ACL activity. In order to verify the significance of
ACL activity in maintaining cellular ATP content in vivo, we over-
expressed ACL in the TA of mice (Figure S2A). In accord with the
in vitro findings, overexpression of ACL increased cellular ATP
content by30% (Figure 4D). Because IGF1 is a strong anabolic
stimulus for skeletal muscle (Egerman and Glass, 2014), we
knocked down ACL by siRNA in human primary myotubes, sub-
jected myotubes to IGF1 treatment, and measured protein syn-
thesis. As shown in Figure S4A, ACL silencing significantly
reduced the increase in protein synthesis and in MHC protein
levels mediated by IGF1 without perturbing basal levels. In addi-
tion, ACL overexpression in human primary myotubes was suffi-(B) Myotubes were infected with AdEV or Ad dn-AKT. Forty-eight hours post-infe
and AKT were analyzed.
(C)Myotubeswere infectedwith AdEV or Admyr-AKT. pACL (S455) and total ACL a
and (C), a blot representative of three independent experiments is shown. Graphs
(D) pACL (T447/S451), pAKT (S473 and T308), and total AKT levels were analyzed in
was used; n = 8 mice/group.
(E and F) Differentiatedmyotubes were subjected to siRNA to ACL and treated wit
with 14C-Na-pyruvate during the last 5 hr of the 24 hr culture, 3 days post-transfec
concentration. Protein extracts were analyzed for ACL expression 4 days post-tra
SEM; n = 3–5; ANOVA followed by Dunnett’s multiple comparison test was used.
test was used. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 versus con
Ccient to increase myotube size and MHC protein levels (Fig-
ure S4B). Interestingly, ACL phosphorylation on T447/S451 and
total ACL levels were decreased in the quadriceps of mice dis-
playing prominent atrophy induced by dexamethasone treat-
ment for 7 days (Figure S4C).
DISCUSSION
ACL has been appreciated for its role in fatty acid (FA) biosyn-
thesis and its requirement in theproductionof acetyl-CoA (Wellen
et al., 2009; Choudhary et al., 2014). However, ACL’s role in other
metabolic processes,particularly in skeletalmuscle, hasnotbeen
extensively studied. Recently, Lee et al. reported that AKT phos-
phorylates and increases the activity of ACL via a PI3K-depen-
dent pathway in cancer cells (Lee et al., 2014). This finding gave
context to our observation that IGF1 was capable of increasing
phospho-ACL levels and de novo lipid synthesis in skeletal mus-
cle in an ACL-dependent manner. Further exploration demon-
strated that ACL was capable of increasing levels of cardiolipin,
a critical component of the mitochondrial membrane that consti-
tutes about 20% of the organelle’s FA composition (Paradies
et al., 2014; Ren et al., 2014), opening up a new arena for ACL-
required biology. ACL was found to be required for maintenance
of cardiolipin, which in turn modulated mitochondrial complex
formation. ACL activity is thus limiting for this critical process—
critical because complex formation modulates ATP levels.
It was previously demonstrated that IGF1 is an anabolic agent
for skeletal muscle; it induces protein synthesis via the AKT/
mTOR pathway and blocks protein breakdown by inhibiting
FOXO induction of the E3 ligases MuRF1 and MAFbx, which
mediate muscle protein degradation (Egerman and Glass,
2014). What hadn’t been understood previously was that IGF1
could also perturb mitochondrial metabolism, as shown in this
study. It seems especially noteworthy that a growth factor that
induces protein synthesis is also able to induce the required
ATP necessary for the production of new proteins, as well as
to facilitate correct protein folding and subsequent protein func-
tion. In contrast, in many settings mitochondrial stimulation has
seemed to be at odds with anabolic protein synthesis. For
example, PGC1a, a transcriptional co-activator that stimulates
mitochondriogenesis, is itself induced by AMPK activation (Lee
et al., 2006), which at the same time actually inhibits mTOR
signaling. Also, anabolic stimuli by mechanisms such as
myostatin inhibition can induce hypertrophy without increasing
mitochondrial function, and this sort of effect in part might
explain why some anabolic stimuli result in more fatigable mus-
cle (LeBrasseur et al., 2009; Mouisel et al., 2014). However, this
study gives at least one physiologic mechanism in which bothction, cells were treated with 30 nM IGF1 for 30 min. pACL (S455) and total ACL
nd AKTwere analyzed 24, 48, and 72 hr post-infection by immunoblotting. In (B)
show densitometric analysis of three independent experiments; unpaired t test.
tibialis muscle of young and old mice by immunoblotting. A Mann-Whitney test
h vehicle or 30 nM IGF1 for 24 hr with or without 3 mMLY294002 (F) concurrently
tion. 14C counts were determined in extracted lipids and normalized to protein
nsfection. (E) Data are expressed as% change of control. Shown are means ±
(F) Shown are mean ± SEM; ANOVA followed by Tukey’s multiple comparison
trol; $ p < 0.05 versus IGF1.
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Figure 2. ACL Regulates Cardiolipin Con-
tent in Skeletal Muscle
(A and B) AAVs expressing ACL (AAV-ACL; A and
B), GFP (AAV-GFP; A and B), AAV-shCtrl (B), or
AAV-shACL (B) were injected into the tibialis. (A)
Cardiolipin content was analyzed by HPTLC
30 days post-injection. Bands were quantified
using ImageJ; shown are means ± SEM; n = 6–8
mice/group; Mann-Whitney test. (B) Transcripts of
Crls1, Taz, and Ptpmt1 were analyzed by qRT-
PCR; data are expressed as fold increase of AAV-
GFP (n = 6–8 mice/group); Wilcoxon test.
(C) Myotubes treated with vehicle or 30 nM IGF1
for 30 hr ± 3 mMLY294002; cardiolipin content was
analyzed by HPTLC. Bands were quantified using
ImageJ. Data are expressed as means ± SEM of
four independent experiments; ANOVA followed
by Tukey’s multiple comparison test was used.
(D–G) Cardiolipin content (D and F) and mRNA
expression of Taz, Ptpmt1, and Crls1 (E and G)
were analyzed by HPTLC and qRT-PCR, respec-
tively, in tibialis of young and old (D and E) and
young exercised or sedentary (F and G) mice.
(D and F) Bands were quantified using ImageJ.
Shown aremeans ± SEM; n = 8mice/group;Mann-
Whitney test. In (E) and (G), data are expressed
as fold increase of young or young/sedentary,
respectively. (E) n = 5–6mice/group; (G) n = 8mice/
group; Mann-Whitney test, *p < 0.05, **p < 0.01,
***p < 0.001.anabolic stimuli and mitochondria might be stimulated—not by
increasing mitochondrial number, but by increasing mitochon-
drial efficiency.872 Cell Metabolism 21, 868–876, June 2, 2015 ª2015 Elsevier Inc.When skeletal muscle ages, there is an
increase in frailty, which is coincident with
a decrease in muscle mass and func-
tion—this condition is called sarcopenia
(Cruz-Jentoft et al., 2010). It has been
shown that one of the major pathways
downregulated at the onset of sarcopenia
is the mitochondrial pathway, such as
those genes involved in OXPHOS and
the TCA cycle (Ibebunjo et al., 2013; Mar-
zetti et al., 2013). A decline in concentra-
tions of circulating IGF1 in sarcopenia
has been described in humans and ro-
dents (O’Connor et al., 1998; Velasco
et al., 1998). This study suggests the pos-
sibility that re-activation of ACL in settings
of sarcopenia might be helpful in restoring
mitochondrial competence. Of interest, in
this study it was observed that phosphor-
ylated ACL is dramatically reduced in old
(24 months) versus young mice, coinci-
dent with a decrease in levels of AKT
phosphorylation with age. Therefore, the
goal would be to reactivate ACL in set-
tings of sarcopenia, perhaps by restoring
IGF1 signaling to physiologic levels in this
setting. It remains to be seen whether ge-netic manipulation of ACL in old mice affects mitochondrial and
skeletal muscle function. Homozygous ACL knockout mice die
early in development (Beigneux et al., 2004); therefore, the
Figure 3. ACL Increases Mitochondrial Complex Content and Activity
(A–C) Mitochondrial proteins extracted from tibialis injected with AAV-GFP or AAV-ACL 30 days post-infection, analyzed for mitochondrial complex and
supercomplex content by Coomassie native PAGE.
(D) Levels of respiratory chain subunits analyzed by immunoblotting (D).
(E and F) In-gel activity assay was carried out for complex I (E) and complex II–V (F).
Graphs show densitometric analysis and data are shown as means ± SEM; *p < 0.05, **p < 0.01; n = 6–7, Mann-Whitney test.
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Figure 4. IGF1 Increases Oxygen Consumption and ATP Content via ACL
(A and B) Myotubes given siRNA to ACL (A and B) or infected with AdEV or AdACL (B). (A) Three days post-transfection, cells were treated for 24 hr with
vehicle or 30 nM IGF1. Oxygen consumption rates (OCR) ± 1.6 mM oligomycin, 0.5 mM fluoro-carbonyl cyanide phenylhydrazone (FCCP), or 1 mM
antimycin + 1.5 mM rotenone were determined using XFe96 extracellular flux analyzer. Graphs show data from three independent experiments; results are
expressed as means ± SEM of the area under the curve (AUC). (B) Three days post-transfection or 2 days post-infection, mitochondria were isolated and
complex activity was measured by ELISA. Activity is expressed as change in absorbance per minute (mOD/min) per mg of cell lysate. Data are shown as
means ± SEM; n = 3.
(C) Human skeletal muscle myotubes were transfected with siCtrl or siACL as described in (A) and (B). Three days post-transfection, myotubes were treated with
30 nM IGF1 for 36 hr, and cellular ATP was analyzed. In parallel, myotubes were transduced with AdEV or AdACL and analyzed for ATP concentration 48 hr post-
infection. Shown are means ± SEM; n = 3.
(D) ATP concentration determined in tibialis of AAV-GFP- or AAV-ACL-injected mice.
Shown are means ± SEM; ANOVA followed by Tukey’s multiple comparison test (A–C), Mann-Whitney test (D); n = 6–7 mice per group, *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001.generation of a skeletal muscle-specific knockout, or perhaps
transgenic mice expressing activated ACL, would be needed
to address this question.
The finding here that ACL induced cardiolipin production,
which has been shown to be required for regulated ATP produc-
tion, provides an important new node in the understanding of en-
ergy metabolism in skeletal muscle. This study opens up future
work aimed at understanding distinct signaling steps that might
be able to induce the required phosphorylation of ACL, moni-
toring cardiolipin levels as a biomarker of this ACL/cardiolipin
pathway. IGF1/AKT/ACL/cardiolipin/ATP constitutes an impor-
tant signaling pathway that is apparently critical for providing
the energy to match the anabolism of IGF1-induced protein
synthesis.874 Cell Metabolism 21, 868–876, June 2, 2015 ª2015 Elsevier Inc.EXPERIMENTAL PROCEDURES
De Novo Lipid Synthesis Assay
Primary human skeletal muscle myotubes were incubated with 14C-Na-pyru-
vate (2 mCi/ml) (PerkinElmer) for 5 hr. The cells were washed four times with
cold PBS and lysed in cold PBS by ultrasound. Lipids were extracted by chlor-
oform:methanol (1:1). Radioactivity was measured using scintillation cocktail
(UltimaGold-XR, PerkinElmer). The values were normalized by protein concen-
tration determined by BCA (Thermo Scientific).
High-Performance Thin-Layer Chromatography
The extracted lipids were dissolved in chloroform:methanol (2:1) and
analyzed by HPTLC LiChrospher silica gel 60F254S (Millipore) using chlorofor-
m:acetone:methanol:acetic acid:water (6:8:2:2:1) asmobile phase. Cardiolipin
sodium salt (Sigma) was dissolved in chloroform:methanol (2:1) and used as
cardiolipin standard/marker. The HPTLC plate was derivatized by spraying
0.18% copper sulfate in orthophosphoric acid:water (40:460) and heating at
200C for 20 min. Lipid bands were quantified by ImageJ.
Mitochondria Isolation
Mitochondria were isolated either from primary human myotubes or tibialis
muscle using Dounce homogenizer with mitochondria isolation buffer
(70 mM sucrose, 220 mM mannitol, 5 mM KH2PO4, 5 mM MgCl2, 2 mM
HEPES, 1 mM EGTA [pH 7.2], and 0.2% FA-free BSA) supplemented with
Halt protease and phosphatase inhibitors, trichostatin, and nicotinamide at
4C. Cell or tissue homogenates were centrifuged at 1,0003 g for 10 min at
4C. The supernatants were subsequently centrifuged at 12,0003 g for
20 min at 4C, and pellets were washed in mitochondria isolation buffer and
stored at 80C until further processing.
Statistical Analysis
Statistical significance was evaluated with one-way analysis of variance
(ANOVA) for multiple groups, followed by Bonferroni’s or Tukey’s post
hoc test to evaluate differences among groups. Mann-Whitney-Wilcoxon
test or unpaired t test was used to compare two groups. All error bars indi-
cate SEM.
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